Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01287845 | PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers | PHASE1 | COMPLETED | 14 | — | — | Feb 1, 2011 | Nov 1, 2011 | Jan 21, 2013 | 2 | United States, Austria |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY1075553 | DRUG | Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1 |
Inclusion Criteria: * Part 1: Healthy volunteers only \-- Males ≥ 40 years of age * Part 2: Prostate cancer patients * Males ≥ 18 years of age * Serum PSA (Prostate-Specific Antigen) value above normal. * Patients had an MRI and/or a positive \[11C\] - or \[18F\] -choline PET/CT for prima...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | NA | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | — | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | NA | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | NA | Undisclosed |
| Unity Health Toronto | UBX | 1 | — | Undisclosed |